About US
Contact us
-
AACR: Novartis aims to keep canakinumab's early lung cancer hopes alive despite metastatic failureWhen Novartis failed in an attempt to repurpose Ilaris for metastatic non-small cell lung cancer (NSCLC), the Swiss pharma played up signs that it said supported continued exploration of the med in e2022/4/14
-
GlaxoSmithKline, CureVac and BioNTech clinch German pandemic preparedness contractsAs CureVac and GlaxoSmithKline mulligan with a second-generation COVID-19 vaccine, the partners have signed on for a German pandemic contingency plan to earmark mRNA production capacity for years to2022/4/12
-
Lilly goes down under to find a partner for failed cancer drug Lartruvo, licensing certain rights to Telix for $5MEli Lilly has pulled failed cancer drug Lartruvo off the scrap heap andlicensedcertain rights to Australian biotech Telix for a mere $5 million. Telix, which is based in Melbourne, will give La2022/4/12
-
Alnylam founder Maraganore snags $10.2M pay in his farewell year, as new CEO Greenstreet grabs $8.6MJohn Maraganore, Ph.D., officially stepped down as CEO of Alnylam Pharmaceuticals at the end of 2021. In his last year leading the RNA interference specialist, the former helmsmangot $10.18 million i2022/4/8
-
A seasonal COVID-19 booster shot? Don't count on it in the U.S. or EuropePeople in the U.S. and Europe hoping to receive COVID-19 vaccine booster shots every four to six months are in for a rude awakening. On Wednesday, experts on both sides of the Atlantic to2022/4/8
-
Novartis gets FDA nod to begin making Zolgensma in North CarolinaNovartis can begin producing its spinal muscular atrophy (SMA) gene therapy, Zolgensma, at its North Carolina plant following FDA'sapproval for amanufacturing licenseat the site. The regulatory2022/4/6
-
Jardiance sparks Boehringer Ingelheim's 2021 growth, with more likely on the wayAmid its global push to reach more patients with SGLT2 inhibitor Jardiance, Boehringer Ingelheimreportedsolid sales growth for the med last year. Now, armed with two new FDA approvals in a span of si2022/4/6
-
As AstraZeneca sounds the slowdown alarm in China, Jefferies beats the drum for growing branded drug marketChina’s aggressive efforts to lower drug costs are unnerving some investors. Just consider AstraZeneca: The largest multinational pharma in China is projecting a mid-single-digit percentage decline i2022/4/2
-
Aurobindo to turn out lights at troubled New Jersey plant, putting 99 jobs on the chopping blockAn Aurobindo plant that received a scathing FDA rebuke several years back is shutting its doors for good. Indian generics giant Aurobindo is closing shop at its Aurolife Pharma unit in Dayton,2022/4/2
-
Roche's Chugai pays Halozyme $25M to access subcutaneous delivery techChugai Pharmaceutical has struck a deal for a subcutaneous drug delivery technology,payingHalozyme Therapeutics $25 million upfront to use its Enhanze enzyme against an undisclosed target. The2022/3/30